This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n19http://linked.opendata.cz/resource/domain/vavai/subjekt/
n3http://linked.opendata.cz/ontology/domain/vavai/
n8http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F67179843%3A_____%2F11%3A00370154%21RIV12-AV0-67179843/
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F67179843%3A_____%2F11%3A00370154%21RIV12-AV0-67179843
rdf:type
n3:Vysledek skos:Concept
dcterms:description
Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after. Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after.
dcterms:title
Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
skos:prefLabel
Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
skos:notation
RIV/67179843:_____/11:00370154!RIV12-AV0-67179843
n3:predkladatel
n19:ico%3A67179843
n5:aktivita
n14:Z n14:I n14:P
n5:aktivity
I, P(1M0508), P(GA203/08/0114), Z(AV0Z40550506), Z(AV0Z60870520)
n5:cisloPeriodika
7
n5:dodaniDat
n7:2012
n5:domaciTvurceVysledku
n16:6326633
n5:druhVysledku
n18:J
n5:duvernostUdaju
n13:S
n5:entitaPredkladatele
n10:predkladatel
n5:idSjednocenehoVysledku
204843
n5:idVysledku
RIV/67179843:_____/11:00370154
n5:jazykVysledku
n17:eng
n5:klicovaSlova
amino acid analogs; L-erythro-3-hydroxyaspartate (L-EHA); D-serine; neurodegenerative diseases; NMDA receptors; pyridoxal-5´-phosphate (PLP)
n5:klicoveSlovo
n6:L-erythro-3-hydroxyaspartate%20%28L-EHA%29 n6:amino%20acid%20analogs n6:D-serine n6:neurodegenerative%20diseases n6:pyridoxal-5%C2%B4-phosphate%20%28PLP%29 n6:NMDA%20receptors
n5:kodStatuVydavatele
NL - Nizozemsko
n5:kontrolniKodProRIV
[1343C504EE59]
n5:nazevZdroje
Current Drug Targets
n5:obor
n15:FR
n5:pocetDomacichTvurcuVysledku
1
n5:pocetTvurcuVysledku
7
n5:projekt
n9:1M0508 n9:GA203%2F08%2F0114
n5:rokUplatneniVysledku
n7:2011
n5:svazekPeriodika
12
n5:tvurceVysledku
Lepšík, Martin Jansa, Petr Konvalinka, Jan Vorlová, Barbora Jirásková-Vaníčková, Jana Ettrich, Rüdiger Hoffman, Hillary Elizabeth
n5:wos
000291640900010
n5:zamer
n8:AV0Z60870520 n8:AV0Z40550506
s:issn
1389-4501
s:numberOfPages
19